Company / Depreciation & Amortization
Allogene Therapeutics, Inc. Depreciation & Amortization History
FY2021-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Depreciation & Amortization
$12.4M
FY2025
5-year range
$4.6M / $14.3M
FY2021-FY2025
Trend
-13.0%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Depreciation & Amortization has fluctuated over the past 5 years, ranging from $5M in FY2021 to $14M in FY2022.
Based on SEC 10-K filings.
$12M in FY2025 with a 3-year CAGR of -4.7%.
Increased from $11M to $12M over the past 2 years.
Depreciation & Amortization over time
Growth rates
- 3-Year CAGR
- -4.7%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- 3-year CAGR of -4.7%, indicating a declining trend.
- In FY2025, depreciation & amortization decreased 13.0% year-over-year.
- Peak depreciation & amortization was recorded in FY2022.
- Lowest depreciation & amortization in the period was in FY2021.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -4.27 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Depreciation & AmortizationValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $12.4M | -13.0% |
| FY2024 | $14.2M | +35.2% |
| FY2023 | $10.5M | -26.6% |
| FY2022 | $14.3M | +210.9% |
| FY2021 | $4.6M | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026